Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
Business Wire India – In a new sub-analysis of the landmark EMPEROR-Preserved® Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and…